Prevalence and incidence of coronary heart disease in strata of the labor force of a Chicago industrial corporation

Stamler, Jeremiah; Lindberg, Howard A.; Berkson, David M.; Shaffer, Aaron B.; Miller, Wilda A.; Poindexter, Ann R.

doi:10.1016/0021-9681(60)90046-1

Cited by 217 publications

(28 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The relationship of hyperlipidaemia to prevalence, incidence and mortality from ischaemic heart disease has been well established (Stamler et al, 1960;Kannel et al, 1971). The results of the WHOsponsored clinical trial of the effects of lowering blood cholesterol by therapeutic intervention with clofibrate in the prevention of ischaemic heart disease clearly demonstrate that reduction of serum cholesterol concentrations is relevant to the prevention of coronary heart disease (Committee of Principal Investigators, 1978).…”

Section: Discussionmentioning

confidence: 99%

Tumorigenicity of the hypolipidaemic peroxisome proliferator ethyl-α-p-chlorophenoxyisobutyrate (clofibrate) in rats

Reddy¹,

Qureshi²

1979

Br J Cancer

140

View full text Add to dashboard Cite

Summary.-Ethyl-a-p-chlorophenoxyisobutyrate (clofibrate), a hypolipidaemic drug which induces hepatomegaly and proliferation of peroxisomes in liver cells of rats and mice, was fed to 15 male F344 rats at a dietary concentration of 0.5%o (v/w) for up to 28 months. Hepatocellular carcinomas developed in 10/11 (91 ,h) rats killed between 24 and 28 months. Other tumours included carcinoma of the pancreas (2 rats), leiomyoma of the small intestine (1 rat) and a large dermatofibrosarcoma (1 rat). Clofibrate is the third hypolipidaemic peroxisome proliferator demonstrated to be hepatocarcinogenic in rats. These studies suggest that hypolipidaemic agents which are capable of producing a sustained hepatomegalic and peroxisome-proliferative effect also induce liver tumours.

show abstract

Section: Discussionmentioning

confidence: 99%

Tumorigenicity of the hypolipidaemic peroxisome proliferator ethyl-α-p-chlorophenoxyisobutyrate (clofibrate) in rats

Reddy¹,

Qureshi²

1979

Br J Cancer

140

View full text Add to dashboard Cite

show abstract

“…Subjects with coronary heart disease are also frequently overweight (3)(4)(5), and a number of studies have demonstrated significant correlations between the serum cholesterol concentration and body fatness. Hypercholesterolemia may therefore be partly attributable to the development of obesity in some patients particularly since it has been shown that a gain in weight is associated with a rise in the plasma cholesterol level (6) and loss of weight with a fall in the cholesterol concentration (7).…”

Section: Introductionmentioning

confidence: 99%

Turnover of Plasma Esterified Cholesterol in Normocholesterolemic and Hypercholesterolemic Subjects and Its Relation to Body Build*

Nestel¹,

Monger²

1967

J. Clin. Invest.

View full text Add to dashboard Cite

Summary. The turnover rate of plasma total esterified cholesterol was measured after the intravenous injection of tritiated mevalonic acid in 16 men with coronary heart disease. Four subjects were normocholesterolemic and 12 were hypercholesterolemic; among the latter, 3 suffered from familial hypercholesterolemia and 6 were overweight.The turnover rate of plasma esterified cholesterol was highest among the overweight hypercholesterolemic subjects and least among the subjects with familial hypercholesterolemia. Hypercholesterolemic subjects of normal weight had turnover rates similar to those found in normocholesterolemic men.Significant correlations were found between body surface or body weight and the turnover rate of plasma esterified cholesterol.We conclude that the factors which determine the development of hypercholesterolemia are not identical in all hypercholesterolemic subjects and that when hypercholesterolemia is associated with overweight there is an increased formation of at least plasma esterified cholesterol.

show abstract

“…Serum cholesterol (18) and tri glyceride ( 10) levels were perfO'rmed after a 14 hom overnight fast 5 times during the 2 month control period and at 2,4,8,12,16,20,24,28,32,36,40,44, and 48 weeks after halofenate O'r placebo was started. All subjects were clinically evaluated for symptoms and given a physical examination when the blood was drawn.…”

Section: Methodsmentioning

confidence: 99%

Effect of halofenate on serum lipids

Aronow

Harding

Khursheed

et al. 1973

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Forty-eight people with hypertriglyceridemia associated with types III, IV, Lang Beach and Irvine, Galif. Cardiology Section, Medical Service, Long Beach Veterans Administration Hospital, and the University of California College of Medicine at IrvineSerum cholesterol and triglyceride abnonnalities, especially of cholesterol, are common in coronary heart disease. 2 A relations hip between the serum cholester-01 level and the relative risk of developing clinical coronary heart disease has been reported by many investigators. 4 , 6, 9, 11, 12, B-1n Other investigators have found that serum tri glycerides are elevated more frequently than serum cholesterol levels in patients with coronary heart disease.

show abstract

Prevalence and incidence of coronary heart disease in strata of the labor force of a Chicago industrial corporation

Cited by 217 publications

References 15 publications

Tumorigenicity of the hypolipidaemic peroxisome proliferator ethyl-α-p-chlorophenoxyisobutyrate (clofibrate) in rats

Tumorigenicity of the hypolipidaemic peroxisome proliferator ethyl-α-p-chlorophenoxyisobutyrate (clofibrate) in rats

Turnover of Plasma Esterified Cholesterol in Normocholesterolemic and Hypercholesterolemic Subjects and Its Relation to Body Build*

Effect of halofenate on serum lipids

Contact Info

Product

Resources

About